Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -13% Improvement Relative Risk c19early.org/e Basheer et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 390 patients in Israel Higher mortality with aspirin (p=0.0003) Basheer et al., Metabolites, doi:10.3390/metabo11100679 Favors aspirin Favors control
Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia
Basheer et al., Metabolites, doi:10.3390/metabo11100679
Basheer et al., Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia, Metabolites, doi:10.3390/metabo11100679
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 390 hospitalized patients in Israel, showing higher risk of mortality with prior aspirin use. Details of the analysis are not provided.
risk of death, 13.0% higher, RR 1.13, p < 0.001, treatment 45 of 140 (32.1%), control 29 of 250 (11.6%), adjusted per study, odds ratio converted to relative risk, group sizes approximated (only percentages provided).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Basheer et al., 2 Oct 2021, retrospective, Israel, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Article Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia Maamoun Basheer 1,*, Elias Saad 1,2,*, Rechnitzer Hagai 3 and Nimer Assy 1,2,* Internal Medicine Department, Galilee Medical Center, Nahariya 2210001, Israel The Azrieli Faculty of Medicine, Bar-Ilan University, Safad 1311502, Israel 3 The Microbiology Lab, Galilee Medical Center, Nahariya 2210001, Israel; HagaiR@gmc.gov.il * Correspondence: maamon.basheer@mail.huji.ac.il (M.B.); eliass@gmc.gov.il (E.S.); nimera@gmc.gov.il (N.A.) 1 2 Abstract: Background/Aim: Early identification of patients with COVID-19 who will develop severe or critical Citation: Basheer, M.; Saad, E.; Hagai, R.; Assy, N. Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia. Metabolites 2021, 11, 679. https://doi.org/10.3390/ disease symptoms is important for delivering proper and early treatment. We analyzed demographic, clinical, immunological, hematological, biochemical and radiographic findings that may be of utility to clinicians in predicting COVID-19 severity and mortality. Methods: Electronic medical record data from patients diagnosed with COVID-19 from November 2020 to June 2021 in the COVID-19 Department in the Galilee Medical Center, Nahariya, Israel, were collected. Epidemiologic, clinical, laboratory and imaging variables were analyzed. Multivariate stepwise regression analyses and discriminant analyses were used to identify and validate powerful predictors. The main outcome measure was invasive ventilation, or death. Results: The study population included 390 patients, with a mean age of 61 ± 18, and 51% were male. The non-survivors were mostly male, elderly and overweight and significantly suffered from hypertension, diabetes mellitus type 2, lung disease, hemodialysis and past use of aspirin. Four predictive factors were found that associated with increased disease severity and/or mortality: age, NLR, BUN, and use of high flow oxygen therapy (HFNC). The AUC or diagnostic accuracy was 87%, with a sensitivity of 97%, specificity of 60%, PPV of 87% and NPP of 91%. The cytokine levels of CXCL-10, GCSF, IL-2 and IL-6 were significantly reduced upon the discharge of severely ill COVID-19 patients. Conclusions: The predictive factors associated with increased mortality include age, NLR, BUN, and use of HFNC upon admission. Identifying those with higher risks of mortality could help in early interventions to reduce the risk of death. metabo11100679 Academic Editor: Amedeo Lonardo Keywords: SARS-COV-2; NLR; high flow; BUN; insulin resistance; mortality; cytokine storm; predictors Received: 20 September 2021 Accepted: 30 September 2021 Published: 2 October 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Highlights: 1. We analyzed demographic, clinical, immunological, hematological, biochemical and radiographic findings. 2. The following four predictive factors were found that were associated with increased disease severity and/or mortality: age, NLR, BUN, and use of high flow oxygen therapy. 3. The AUC or diagnostic accuracy was 87%, with a sensitivity of 97. 4. Identifying those with higher risks of mortality could help in early interventions to reduce the risk of death.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit